CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran
Abstract
Background: Exposure to endogenous hormones such as estrogen is known as a lifetime Breast Cancer (BC) risk factor. Polymorphisms in genes that are involved in the steroidogenic process, such as Cytochrome P450c17alpha (CYP17), affect individuals’ susceptibility to BC. In Iran, the highest incident of BC is among young women. This study aimed to find prevalence of Single Nucleotide Polymorphisms (SNPs) in genes such as CYP17 and significant correlation with age-oriented group of breast cancer.
Methods: In 2016, a case series study was conducted on a total population of 205 patients suffering from breast cancer referred to Cancer Institute, Imam Khomeini Hospital Complex, Tehran, Iran. This population consisted of 104 cases less than 40 yr old and 101 cases over 40. The genotype variants of CYP17 MspA1 were determined using PCR, followed by RFLP. The association of CYP17 MspA1 polymorphisms with the risk of BC in two different age groups was evaluated by calculating odds ratio and 95% confidence intervals using unconditional logistic regression.
Results: Carriers of at least one A2 allele may have higher risk of developing breast cancer at younger age compared to patients with A1/A1 genotype (Odds Ratio: 1.99, 95% Confidence Interval: 1.11-3.57, P=0.02).
Conclusion: CYP17gene polymorphisms may have influence on the early onset of breast cancer.
Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, Barberini F, Rulli A (2009). CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer, 20;9:115.
Babu GR, Samari G, Cohen SP, Mahapatra T, Wahbe RM, Mermash S, Galal OM (2011). Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev, 12:1647-1655.
Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni S, Montazeri A, Momtahen A, Kashefi A, Ebrahimi M (2011). Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol, 22:93-97.
Yager JD, Davidson NE (2006). Estrogen carcinogenesis in breast cancer. N Engl J Med, 354:270-282.
Dumitrescu R, Cotarla I (2005). Understanding breast cancer risk‐where do we stand in 2005? J Cell Mol Med, 9:208-221.
Yue W, Santen R, Wang J-P, Li Y, Verderame M, Bocchinfuso W, Korach K, Devanesan P, Todorovic R, Rogan E (2003). Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol, 86:477-486.
De Bont R, Van Larebeke N (2004). Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis, 19:169-185.
Yoshimoto FK, Auchus RJ (2015). The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1). J Steroid Biochem Mol Biol, 151:52-65.
Reid AH, Attard G, Barrie E, de Bono JS (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol, 5:610-620.
van den Akker EL, Koper JW, Boehmer AL, Themmen AP, Verhoef-Post M, Timmerman MA, Otten BJ, Drop SL, De Jong FH (2002). Differential inhibition of 17α-hydroxylase and 17, 20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab, 87:5714-5721.
Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE (2015). Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control, 26:319-332.
Setiawan VW, Schumacher FR, Haiman CA et al (2007). CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev, 16:2237-2246.
Rannala B (2001). Finding genes influencing susceptibility to complex diseases in the post-genome era. Am J Pharmacogenomics, 1:203-221.
Sharp L, Cardy AH, Cotton SC, Little J (2004). CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. Am J Epidemiol, 160:729-740.
Ye Z, Parry JM (2002). The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis, 17:119-126.
Rai R, Sharma KL, Misra S, Kumar A, Mittal B (2014). CYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco users. Tumour Biol, 35:6531-6537.
Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, Bhat HK (2008). Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol, 232:78-85.
Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997). A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57:1063-1065.
Bergman‐Jungeström M, Gentile M, Lundin AC, Wingren S (1999). Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer, 84:350-353.
Mao C, Wang X-W, He B-F, Qiu L-X, Liao R-Y, Luo R-C, Chen Q (2010). Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls. Breast Cancer Res Treat, 122:259-265.
Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Tołoczko-Grabarek A, Gilbert M, Edler L, Zapatka M (2010). BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat, 119:201-211.
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma V-M, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2000). Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev, 9:1343-1348.
Kristensen VN, Haraldsen EK, Anderson KB, Lønning P, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale A-L (1999). CYP17 and Breast Cancer Risk The Polymorphism in the 5′ Flanking Area of the Gene Does Not Influence Binding to Sp-1. Cancer Res, 59:2825-2828.
Chakraborty A, Murthy N, Chintamani C, Bhatnagar D, Mohil R, Sharma P, Saxena S (2007). CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet, 52:159-165.
Cristina Tote Franco Pinotti S, da Silva IDCG, Carvalho CV, Nazário ACP (2012). MspA1 polymorphism of the CYP17 gene in breast cysts. Gynecol Endocrinol, 28:443-446.
Chang J-H, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie M, Giles GG, Chenevix-Trench G (2005). CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res, 7:R513-R521.
Santos SS, Jácome GPO, Koifman R, Koifman S (2014). CYP17, CYP19, and NQO1 Genetic Polymorphisms and Breast Cancer Susceptibility in Young Women in Brazil. Br J Med Med Res, 4:68.
Yao L, Fang F, Wu Q, Yang Z, Zhong Y, Yu L (2009). No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects. Breast Cancer Res Treat, 122:221-227.
Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF (2000). CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst, 92:1674-1681.
Shin MH1, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D (2005). Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med, 37:11-17.
TÜZÜNER BM, Öztürk T, Kisakesen HI, Ilvan Ş, Zerrin C, Öztürk O, Isbir T (2010). CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility. In Vivo, 24:71-74.
Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005). CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res, 7:R455-R464.
Dvornyk V1, Waqar-ul-Haq (2012). Genetics of age at menarche: a systematic review. Hum Reprod Update, 18:198-210.
Pei Y-F, Zhang L, Deng H-W, Dvornyk V (2008). CYP17 MspA1 polymorphism and age at menarche: a meta-analysis. Dis Markers, 25:87-95.
| Files | ||
| Issue | Vol 46 No 4 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Breast cancer CYP17 gene Early onset breast cancer Estrogen Late-onset breast cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
